Cargando…
The miRNAs Role in Melanoma and in Its Resistance to Therapy
Melanoma is the less common but the most malignant skin cancer. Since the survival rate of melanoma metastasis is about 10–15%, many different studies have been carried out in order to find a more effective treatment. Although the development of target-based therapies and immunotherapeutic strategie...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037367/ https://www.ncbi.nlm.nih.gov/pubmed/32013263 http://dx.doi.org/10.3390/ijms21030878 |
_version_ | 1783500411422900224 |
---|---|
author | Varrone, Francesca Caputo, Emilia |
author_facet | Varrone, Francesca Caputo, Emilia |
author_sort | Varrone, Francesca |
collection | PubMed |
description | Melanoma is the less common but the most malignant skin cancer. Since the survival rate of melanoma metastasis is about 10–15%, many different studies have been carried out in order to find a more effective treatment. Although the development of target-based therapies and immunotherapeutic strategies has improved chances for patient survival, melanoma treatment still remains a big challenge for oncologists. Here, we collect recent data about the emerging role of melanoma-associated microRNAs (miRNAs) currently available treatments, and their involvement in drug resistance. We also reviewed miRNAs as prognostic factors, because of their chemical stability and resistance to RNase activity, in melanoma progression. Moreover, despite miRNAs being considered small conserved regulators with the limitation of target specificity, we outline the dual role of melanoma-associated miRNAs, as oncogenic and/or tumor suppressive factors, compared to other tumors. |
format | Online Article Text |
id | pubmed-7037367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70373672020-03-11 The miRNAs Role in Melanoma and in Its Resistance to Therapy Varrone, Francesca Caputo, Emilia Int J Mol Sci Review Melanoma is the less common but the most malignant skin cancer. Since the survival rate of melanoma metastasis is about 10–15%, many different studies have been carried out in order to find a more effective treatment. Although the development of target-based therapies and immunotherapeutic strategies has improved chances for patient survival, melanoma treatment still remains a big challenge for oncologists. Here, we collect recent data about the emerging role of melanoma-associated microRNAs (miRNAs) currently available treatments, and their involvement in drug resistance. We also reviewed miRNAs as prognostic factors, because of their chemical stability and resistance to RNase activity, in melanoma progression. Moreover, despite miRNAs being considered small conserved regulators with the limitation of target specificity, we outline the dual role of melanoma-associated miRNAs, as oncogenic and/or tumor suppressive factors, compared to other tumors. MDPI 2020-01-29 /pmc/articles/PMC7037367/ /pubmed/32013263 http://dx.doi.org/10.3390/ijms21030878 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Varrone, Francesca Caputo, Emilia The miRNAs Role in Melanoma and in Its Resistance to Therapy |
title | The miRNAs Role in Melanoma and in Its Resistance to Therapy |
title_full | The miRNAs Role in Melanoma and in Its Resistance to Therapy |
title_fullStr | The miRNAs Role in Melanoma and in Its Resistance to Therapy |
title_full_unstemmed | The miRNAs Role in Melanoma and in Its Resistance to Therapy |
title_short | The miRNAs Role in Melanoma and in Its Resistance to Therapy |
title_sort | mirnas role in melanoma and in its resistance to therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037367/ https://www.ncbi.nlm.nih.gov/pubmed/32013263 http://dx.doi.org/10.3390/ijms21030878 |
work_keys_str_mv | AT varronefrancesca themirnasroleinmelanomaandinitsresistancetotherapy AT caputoemilia themirnasroleinmelanomaandinitsresistancetotherapy AT varronefrancesca mirnasroleinmelanomaandinitsresistancetotherapy AT caputoemilia mirnasroleinmelanomaandinitsresistancetotherapy |